FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382601691> ?p ?o ?g. }

• W4382601691 endingPage "e763" @default.
• W4382601691 startingPage "e763" @default.
• W4382601691 abstract "Mycoplasma pneumoniae was a common cause of respiratory tract infections before the COVID-19 pandemic, with worldwide incidence of 8·61% from 2017 to 2020, measured by direct test methods.1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar However, non-pharmaceutical interventions (NPIs) against COVID-19 drastically lowered the transmission of M pneumoniae. In the short term, the incidence was down to 1·69% between 2020 and 2021. Lower transmission was also observed for other pathogens at the time.1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar However, M pneumoniae transmission also showed long-term reductions during periods with relaxed or discontinued NPIs, with an incidence of 0·70% between 2021 and 2022.2Meyer Sauteur PM Chalker VJ Berger C Nir-Paz R Beeton ML Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?.Lancet Microbe. 2022; 3: e897Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar During the same period infections with other pathogens resurged, indicating increased community transmission.2Meyer Sauteur PM Chalker VJ Berger C Nir-Paz R Beeton ML Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?.Lancet Microbe. 2022; 3: e897Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar The low incidence of M pneumoniae led to initiation of the first global prospective surveillance study of M pneumoniae by our international collaborative network.1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar, 2Meyer Sauteur PM Chalker VJ Berger C Nir-Paz R Beeton ML Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?.Lancet Microbe. 2022; 3: e897Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar The network was expanded to new countries and sites to track M pneumoniae in real time in the third year after implementation of NPIs against COVID-19 (from April 1, 2022, to March 31, 2023). The prospective global dataset included 42 sites in 23 countries in Europe, Asia, the Americas, and Oceania (appendix pp 6–9). The mean incidence of M pneumoniae detected by PCR during the 12-month study period was 0·82% (SD 2·36; appendix pp 10–12). Overall, M pneumoniae was detected by PCR in only 214 (0·10%) of 212 207 tests (appendix p 13); positive PCR results were reported in Europe and Asia, but not Oceania or the Americas, except for Cuba, where two positive results were found. Detections by IgM and IgG serology were 306 (7·13%) of 4294, and 574 (13·78%) of 4164, respectively (appendix 10–12). National surveillances in Belgium and Finland reported only positive test numbers—194 in Belgium found by direct test methods with the use of various techniques, and 348 in Finland found predominantly with the use of serology—but not the total number of people tested (appendix pp 10–12). These prospective data for M pneumoniae show that, to our knowledge, the only absent respiratory pathogen was M pneumoniae after long periods with discontinued NPIs worldwide. Of the various speculations about the global unprecedented suppression of M pneumoniae infections immediately after the implementation of NPIs,1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar most could be ruled out given the sustained absence of M pneumoniae after long periods with discontinued NPIs. A hypothesis concerning a direct biological effect of SARS-CoV-2 on M pneumoniae has not been rejected, but supporting data do not exist. Transient herd immunity from M pneumoniae epidemics between April, 2019, and March, 2020, in several countries in Europe and Asia1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar is another hypothesis. Previously collected data indicated an interval of 1–3 years between M pneumoniae epidemics in Europe and Israel.3Beeton ML Zhang XS Uldum SA et al.Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.Euro Surveill. 2020; 251900112Crossref PubMed Scopus (16) Google Scholar Thus, a resurgent peak in Europe would have been expected by March, 2023. We observed declining detections of M pneumoniae-specific IgM and IgG antibodies by serology from 2020 to 2023,1Meyer Sauteur PM Beeton ML Uldum SA et al.Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.Euro Surveill. 2022; 272100746Crossref PubMed Scopus (8) Google Scholar, 2Meyer Sauteur PM Chalker VJ Berger C Nir-Paz R Beeton ML Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?.Lancet Microbe. 2022; 3: e897Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar consistent with waning herd immunity. Resurgence of M pneumoniae has not yet been observed. If M pneumoniae infections resurge, they might affect the world population,4Nygaard U Hartling UB Nielsen J et al.Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study.Lancet Child Adolesc Health. 2023; 7: 171-179Summary Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 5Bamford A Whittaker E Resurgence of group A streptococcal disease in children.BMJ. 2023; 380: 43Crossref PubMed Scopus (0) Google Scholar which has not been exposed to M pneumoniae for the past 3 years, and result in an increase in rare severe disease and extrapulmonary manifestations.2Meyer Sauteur PM Chalker VJ Berger C Nir-Paz R Beeton ML Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?.Lancet Microbe. 2022; 3: e897Summary Full Text Full Text PDF PubMed Scopus (1) Google Scholar Our continuous surveillance will lead to early detection of a resurgence of M pneumoniae, and will allow a prompt response with adequate management of re-emerging infections. We declare no competing interests. Download .pdf (.43 MB) Help with pdf files Supplementary appendix" @default.
• W4382601691 created "2023-06-30" @default.
• W4382601691 creator A5000405996 @default.
• W4382601691 creator A5002806402 @default.
• W4382601691 creator A5004439664 @default.
• W4382601691 creator A5004481160 @default.
• W4382601691 creator A5008838383 @default.
• W4382601691 creator A5009498023 @default.
• W4382601691 creator A5010272337 @default.
• W4382601691 creator A5010738620 @default.
• W4382601691 creator A5012711878 @default.
• W4382601691 creator A5015066030 @default.
• W4382601691 creator A5015071191 @default.
• W4382601691 creator A5015911101 @default.
• W4382601691 creator A5018133311 @default.
• W4382601691 creator A5019185269 @default.
• W4382601691 creator A5019353779 @default.
• W4382601691 creator A5020211200 @default.
• W4382601691 creator A5021477687 @default.
• W4382601691 creator A5023675979 @default.
• W4382601691 creator A5025455152 @default.
• W4382601691 creator A5026768340 @default.
• W4382601691 creator A5027056035 @default.
• W4382601691 creator A5027786740 @default.
• W4382601691 creator A5029665155 @default.
• W4382601691 creator A5030862602 @default.
• W4382601691 creator A5031053966 @default.
• W4382601691 creator A5031875302 @default.
• W4382601691 creator A5032468724 @default.
• W4382601691 creator A5033695137 @default.
• W4382601691 creator A5034667055 @default.
• W4382601691 creator A5035628170 @default.
• W4382601691 creator A5036820505 @default.
• W4382601691 creator A5037270073 @default.
• W4382601691 creator A5037287149 @default.
• W4382601691 creator A5038091461 @default.
• W4382601691 creator A5040250194 @default.
• W4382601691 creator A5042351255 @default.
• W4382601691 creator A5042622188 @default.
• W4382601691 creator A5043694253 @default.
• W4382601691 creator A5044179986 @default.
• W4382601691 creator A5046956119 @default.
• W4382601691 creator A5047514615 @default.
• W4382601691 creator A5049115992 @default.
• W4382601691 creator A5050120362 @default.
• W4382601691 creator A5051289978 @default.
• W4382601691 creator A5051935462 @default.
• W4382601691 creator A5052791618 @default.
• W4382601691 creator A5053471573 @default.
• W4382601691 creator A5053893299 @default.
• W4382601691 creator A5054077206 @default.
• W4382601691 creator A5054879659 @default.
• W4382601691 creator A5059108311 @default.
• W4382601691 creator A5060733808 @default.
• W4382601691 creator A5060946833 @default.
• W4382601691 creator A5061310423 @default.
• W4382601691 creator A5061543209 @default.
• W4382601691 creator A5061966732 @default.
• W4382601691 creator A5061988716 @default.
• W4382601691 creator A5062689808 @default.
• W4382601691 creator A5063890462 @default.
• W4382601691 creator A5064245613 @default.
• W4382601691 creator A5065203695 @default.
• W4382601691 creator A5067299658 @default.
• W4382601691 creator A5068183127 @default.
• W4382601691 creator A5070844563 @default.
• W4382601691 creator A5077605323 @default.
• W4382601691 creator A5078973639 @default.
• W4382601691 creator A5079460182 @default.
• W4382601691 creator A5080287773 @default.
• W4382601691 creator A5082269945 @default.
• W4382601691 creator A5082417498 @default.
• W4382601691 creator A5089222400 @default.
• W4382601691 creator A5089654280 @default.
• W4382601691 creator A5091293579 @default.
• W4382601691 creator A5092362445 @default.
• W4382601691 creator A5092362446 @default.
• W4382601691 date "2023-10-01" @default.
• W4382601691 modified "2023-10-17" @default.
• W4382601691 title "Mycoplasma pneumoniae: gone forever?" @default.
• W4382601691 cites W3000638201 @default.
• W4382601691 cites W4280497858 @default.
• W4382601691 cites W4290999031 @default.
• W4382601691 cites W4313855532 @default.
• W4382601691 cites W4315477653 @default.
• W4382601691 doi "https://doi.org/10.1016/s2666-5247(23)00182-9" @default.
• W4382601691 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37393927" @default.
• W4382601691 hasPublicationYear "2023" @default.
• W4382601691 type Work @default.
• W4382601691 citedByCount "0" @default.
• W4382601691 crossrefType "journal-article" @default.
• W4382601691 hasAuthorship W4382601691A5000405996 @default.
• W4382601691 hasAuthorship W4382601691A5002806402 @default.
• W4382601691 hasAuthorship W4382601691A5004439664 @default.
• W4382601691 hasAuthorship W4382601691A5004481160 @default.
• W4382601691 hasAuthorship W4382601691A5008838383 @default.
• W4382601691 hasAuthorship W4382601691A5009498023 @default.
• W4382601691 hasAuthorship W4382601691A5010272337 @default.

• next